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Abstract
Goals—To estimate hepatocellular carcinoma surveillance in the Medicaid cirrhotic population.
Background—Most studies predate 2005 AASLD surveillance recommendations and do not
examine the primary target population, cirrhotics.
Study—For 2006-2007 we identified adults with at least one cirrhosis International Classification
of Disease code and 15 months of continuous enrollment in North Carolina Medicaid, recording
claims for abdominal ultrasound, computed tomography, magnetic resonance imaging, and alpha-
fetoprotein testing. We used multi-variable logistic regression to identify factors independently
associated with imaging.
Results—Five-thousand sixty one subjects (5,061) were identified: mean age 54 years, 54%
male, 35% African-American, 56% White. Cirrhosis risk factors were alcohol (59%), hepatitis C
(30%), hepatitis B (4%), other (18%), and unknown (24%). Only 26% had at least one imaging
test. Just 12% of those not hospitalized or seen in an emergency department had any imaging.
Care in an academic facility, younger age, female gender, viral hepatitis, and Medicare co-
insurance were positively associated with imaging. Twenty-one percent saw a gastroenterologist
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which increased the odds of undergoing imaging [Odds Ratio (O.R.) 2.81, 95% Confidence
Interval (C.I.) 2.32, 3.41] while primary care visits did not (O.R. 0.94, 95% C.I. 0.76, 1.16).
Conclusions—Only a quarter of North Carolina Medicaid cirrhotics had abdominal imaging
over a 15 month period, and many tests may have occurred without surveillance intent.
Gastroenterology visits nearly tripled the odds of imaging, but primary care visits had no effect.
Efforts to improve surveillance rates in cirrhotic patients should target primary care and increased
access to sub-specialty care.
Keywords
screening; quality of care; guidelines; administrative data; health services
Introduction
Hepatocellular carcinoma (HCC) is a leading cause of death in patients with cirrhosis.(1, 2)
Moreover, the rate of HCC in patients with cirrhosis is rising(3, 4) and among men, HCC
carries the fastest growing death rate of all cancers in the US.(5) In 2005, the American
Association for the Study of Liver Diseases (AASLD) recommended HCC surveillance
every 6 to 12 months based on randomized controlled trial evidence that surveillance could
reduce mortality.(3, 6) Therefore, it is important to examine baseline surveillance rates and
variation for this aggressive malignancy.
Several studies have provided estimates of HCC surveillance prior to the 2005 guidelines,
(7-9) one in the target population of patients with cirrhosis.(10) However, most estimates
were based on gastroenterologist’s self-reported surveillance rates, estimates from patients
who ultimately developed HCC, and older populations who may undergo less surveillance
due to age-related risks of morbidity from HCC therapies.
No studies have examined the Medicaid population that typically has less expendable
income and less access to health care services. Also, all previous analyses mentioned have
examined surveillance in years prior to publication of the 2005 AASLD guidelines.
Therefore, we used an administrative health claims database to examine the utilization of
abdominal imaging as a surrogate for surveillance in a Medicaid population of adult
cirrhotics without prior diagnosis of HCC, limited to data after 2005.
Materials and Methods
Study Design
We ascertained performance of abdominal imaging and AFP testing among North Carolina
(NC) Medicaid members with at least 15 months of continuous enrollment during
2006-2007. Although surveillance is recommended for cirrhotic individuals every 6-12
months,(3) we expanded the observation period to 15 months in order to capture imaging
events just outside of this range.
Data Source
The North Carolina Cost and Quality Initiative (C.C.Q.I.) database contains de-identified
billing information, including diagnostic (International Classification of Disease, I.C.D.-9)
and procedural (Current Procedural Terminology, C.P.T.) codes, clinic visits, provider
codes, hospitalization codes, and basic demographics for the North Carolina (NC) Division
of Medical Assistance or NC Medicaid. All billing information was obtained for covered
subjects. This included data from Medicare dual-eligible subjects but did not include
subjects with private insurance obtained individually or through an employer. The authors
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and administrators of the C.C.Q.I. received approval from the NC Department of Medical
Assistance prior to initiation and publication of this work.
Study Population
We included all individuals over the age of 18 with 1) at least one distinct recording of
either I.C.D.-9 code 571.2 (alcoholic cirrhosis of liver) or I.C.D.-9 code 571.5 (cirrhosis of
liver without mention of alcohol), and 2) at least 15 months of continuous Medicaid
enrollment during 2006-2007. The 15 months of enrollment occurred after the index
diagnostic code. When subjects had codes for both alcoholic and non-alcoholic cirrhosis,
they were classified as having alcoholic cirrhosis. Patients were excluded if they also had
HCC (155.0) or procedure codes indicative of HCC treatment (e.g. hepatic resection,
ablation, transplantation) prior to the first cirrhosis diagnostic code. Risk factors for cirrhosis
were also identified and included chronic hepatitis B (070.52), chronic hepatitis C (070.54),
hemochromatosis (275), alpha1-antitrypsin deficiency (273.4), other chronic non-alcoholic
liver disease (571.8), other chronic active hepatitis (571.49), primary biliary cirrhosis
(571.6), cholangitis (576.1) and alcohol abuse (571.0-571.3; 303). There are no dedicated
I.C.D.-9 codes for auto-immune liver disease, non-alcoholic fatty liver disease, or primary
sclerosing cholangitis. The presence (or absence) of risk factors was determined by ICD-9
codes occurring during the 15 months of enrollment.
Surveillance Definition
Our primary outcome was receipt of at least one radiographic exam that could be used for
HCC surveillance over the 15-month observation period. This included abdominal
ultrasound, which is the method preferred by the AASLD.(3) However, the sensitivity of
ultrasound in detecting small focal liver lesions in patients with cirrhosis is lower than either
computed tomography (CT) or magnetic resonance imaging (MRI),(11) possibly leading
some individual providers to choose these modalities for surveillance despite the AASLD
guidelines. Therefore, we ascertained all instances of abdominal ultrasound [complete
abdominal ultrasound (C.P.T. 76700), or limited abdominal ultrasound (C.P.T. 76705)],
abdominal computed tomography (CT) with or without contrast (C.P.T. 74170), or magnetic
resonance imaging (MRI) of the abdomen with or without contrast (C.P.T. 74183). As it is
not considered a stand-alone surveillance test,(3) alpha-fetoprotein (AFP) serum testing
(C.P.T. 82105) was recorded but not included in the primary outcome. Administrative data
does not contain information regarding the indication for exams, and we could not
differentiate between true surveillance exams and diagnostic tests. Therefore, we refer to the
primary outcome as receipt of “imaging” and not “surveillance”.
Variables Examined
In addition to risk factors for cirrhosis, we analyzed demographic data such as age, gender,
race, and county of residence as well as health services characteristics such as visits to
primary care and gastroenterology, care in an academic facility, Medicare co-insurance
status, rural versus urban residence, emergency department encounters, and hospitalizations.
Race/ethnicity was defined by NC Medicaid and was examined to investigate potential
disparities in care. Visits to primary care or gastroenterology were outpatient episodes of
care classified by the provider’s self-defined specialty. Care in an academic facility was
defined as any episode of care in one of the five academic teaching hospitals in North
Carolina. Rural versus urban county of residence was based on the North Carolina Rural
Databank designation.(12) Information on number and type of medical co-morbidities was
collected to calculate the Deyo modification of the Charlson comorbidity index.(13) This
was used to adjust for a subject’s general clinical severity.
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Subgroup analyses excluding subjects over 70 years old, those with at least two or three
distinct I.C.D.-9 codes for cirrhosis, and those who were not hospitalized or seen in an
emergency department (E.D.) were performed. Many cirrhotics over 70 are likely ineligible
for HCC treatments such as chemoembolization or transplantation, thus obviating the need
for surveillance. Use of multiple I.C.D. cirrhosis codes may reduce much of the inadvertent
misclassification of non-cirrhotics as cirrhotic. The third subgroup analysis was to evaluate
the potential for miss-classification of surveillance versus diagnostic exams, as we
hypothesized that exams ordered for patients who never required hospitalization or an E.D.
visit would have a higher likelihood of being a surveillance exam. Given that the source of
data was administrative claims, information on severity of cirrhosis and specific laboratory
or diagnostic testing results was not available.
Two additional subgroup analyses excluded those subjects who developed HCC during the
time of the study to avoid capturing exams that were performed in evaluation of cancer. We
also examined utilization limited to ultrasound use only, the preferred surveillance modality.
Statistical Analysis
Standard univariate statistics were performed, including calculations of means, medians,
proportions, ranges and interquartile ranges. Continuous variables were examined in simple
continuous form as well as categorical forms in order to determine the most valid and
precise coding structure. Bivariate statistics (Pearson’s chi-square, Wilcoxon rank-sum, or t-
tests based on variable type) were used to assess for statistical associations between the
receipt of imaging and the exposures of interest. We performed multivariable logistic
regression to determine independent factors associated with imaging and adjusted for co-
morbidities and frequency of cirrhosis diagnostic codes as a proxy of health services
utilization (primary care visits were not used as this was considered a variable of interest).
As each exposure was considered of potential interest, all risk factors were retained in the
final model regardless of the significance in bivariate analysis. Age was significant in a
linear fashion in bivariate testing in all ways examined. Therefore, it was left as a continuous
variable in the final model. Stata statistical software (Stata Ver. 10.0, College Station,
Texas) was used for all analyses. The study protocol was granted exemption from full
review by the Institutional Review Board at the University of North Carolina Chapel Hill
because it involved the use of existing, de-identified data.
Results
Study population
Five thousand and sixty-one subjects met inclusion criteria after exclusion of 180 due to the
diagnosis of HCC or procedures used to treat HCC. Table 1 shows the demographic
information for this cohort. Fifty-six percent were White, 35% African American, 2%
Native American, 0.5 % Asian American, and 6% other/unreported. A significant proportion
of the sample lived in a rural county (42%). Subjects were seen more often under acute-care
settings than in outpatient clinic visits—70% were seen at least once in an E.D. or were
hospitalized. Forty-eight percent had one or more visits to a primary care physician (median
visits 9, mean 12) and only 21% were seen by a gastroenterologist (median visits 0, mean 2).
Alcohol use or abuse diagnostic codes were identified in 59%.[Table 2] Thirty percent had
hepatitis C, and the prevalence of other risk factors such as hemochromatosis, non-alcoholic
steatohepatitis, primary biliary cirrhosis, hepatitis B, and alph-1 antitrypsin deficiency was
less than 10%. No identifiable risk factors were found in 24%. HCC developed in 77(2%)
over the time of the study.
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Of the 5,061 patients, only 1,268 (26%) underwent at least one exam that could be used for
HCC surveillance over 15 months. AFP testing alone was performed for an additional 4%.
When limited to ultrasound use, only 17% of the sample underwent imaging. Abdominal
ultrasound was the most commonly ordered radiographic study (38% of total imaging). CT
and MRI were ordered in approximately equal frequencies (18% and 16% respectively). Of
those who received imaging, 743 (59%) received just one imaging test, while 304 (24%) had
2 and 221 (17%) had >2. While not considered adequate for surveillance, AFP was
performed at least once in 608 (12%) patients.
Variables associated with imaging
In bivariate analysis, all factors save urban residence, race, Medicare dual-eligibility, and
alpha-1 antitrypsin deficiency showed significant differences in imaging rates (data not
shown). However, in multivariate analysis, female sex (O.R. 1.18, 95% C.I. 1.02, 1.37), at
least one episode of care in an academic center (O.R. 2.13, 95% C.I. 1.82, 2.50), Medicare
dual-eligibility (O.R. 1.69, 95% C.I. 1.38, 2.07), viral related cirrhosis (O.R. 1.98, 95% C.I.
1.67, 2.35), alcohol related cirrhosis (O.R. 1.20, 95% C.I. 1.00, 1.47), and other cirrhosis
with recognized risk factors (other chronic hepatitis or nonalcoholic liver disease,
cholangitis, alpha-1 antitrypsin deficiency, primary biliary cirrhosis, or hemochromatosis;
O.R. 2.16, 95% C.I. 1.79, 2.6) were associated with increased odds of imaging.[Table 3]
Subjects of Asian race had 2.22 times the odds of imaging; however, this result was not
statistically significant (95% C.I 0.90, 5.5). At least one visit to a gastroenterologist (O.R.
2.81, 95% C.I. 2.32, 3.41) impacted the probability of imaging whereas visits to primary
care did not (O.R. 0.94, 95% C.I. 0.76, 1.16). Advancing age was associated with a
decreased probability of imaging (p<0.001).
Subgroup Analyses
We performed several analyses to examine utilization in various subgroups. Imaging
utilization was similar when limited to patients under the age of 70 (4,488 subjects, 89% of
the sample, 26% receiving imaging) and only slightly higher in subjects with at least 2
I.C.D.-9 codes for cirrhosis (3,490 subjects, 69% of the sample, 28% receiving imaging) or
at least 3 I.C.D.-9 codes for cirrhosis (2,853 subjects, 59% of the sample, 31% receiving
imaging). Fifty-seven percent were seen at least once in an E.D. and 47% were hospitalized.
Of these, 1,103 (31%) had abdominal imaging versus 185 (12%) of those not hospitalized or
seen in an E.D. (p<0.0001). The percentage of subjects undergoing imaging was only 1%
lower among those who did not develop HCC (4,984 subjects, 98% of the sample, 25%
receiving imaging). The factors found to significantly impact the probability of imaging in
multivariable analysis persisted even when limited to subjects below the age of 70, subjects
with two or three codes for cirrhosis, subjects who were not hospitalized or seen in an E.D,
and among subjects who did not develop HCC save a few notable exceptions. Subjects with
alcohol-related cirrhosis were slightly more likely to undergo imaging when limited to
subjects under the age of 70 (O.R. 1.27, 95% C.I. 1.04, 1.55) or to those with at least 2 or 3
codes for cirrhosis (O.R. 1.35, 95% C.I. 1.06, 1.72 at least 2 codes; O.R. 1.39, 95% C.I.
1.06, 1.84 at least 3 codes). For those not hospitalized or seen in an E.D., the age of the
subject and the subject’s sex was no longer an important factor. Also for patients seen only
in non-urgent settings, viral hepatitis became the factor with the highest odds of undergoing
imaging (O.R. 4.44, 95% C.I. 2.81, 7.01), and being seen in a university setting had the next
highest odds of undergoing imaging (O.R. 3.46, 95% C.I. 2.29, 5.24).
When limited to ultrasound imaging alone, the same factors were found to be significant,
though there were some differences in point estimates [Table 3]. One notable difference was
in the odds of undergoing ultrasound imaging among Asian-Americans, which showed a
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non-significant decrease in the likelihood of undergoing an ultrasound (O.R. 0.59, 95% C.I.
0.16, 2.17).
Discussion
Medicaid benefits provide crucial coverage to persons with limited or no income, allowing
access to preventive services that might otherwise be forsaken in favor of other necessities.
However, utilization of preventive services such as Pap smear testing, mammograms, or
colonoscopy is suboptimal.(14-16) Surveillance for HCC is no different, as we found that
only one quarter of the NC Medicaid population underwent an exam that could be used for
surveillance over a 15-month observation period, falling to 12% for the 1520 patients who
were only seen in outpatient settings. Ideally, all eligible patients should have undergone at
least one imaging exam. While care in an academic center or seeing a gastroenterologist
increased the odds of imaging, seeing a primary care provider did not.
Two prior studies of patients with HCC examined surveillance rates in VA and Medicare
populations. Despite being older (average age 75 years), 38% of the Medicare population
had prior surveillance(9) compared to only 28% of VA patients with HCC.(8) Another study
of VA hepatitis C cirrhotics without HCC yielded a rate of 42%,(10) highlighting the
potential differences in surveillance rates when patients with or without HCC are examined.
However, all previous studies used data gathered before or during 2005 when the AASLD
guidelines were first published. No studies have examined the Medicaid population. We
found the imaging rate (which we took as a surrogate for surveillance rate) in the Medicaid
population is one of the lowest reported at just 26%. If we limit our analysis to just
ultrasound exams, the AASLD recommended screening tool, the rate falls to 17%.
There are multiple reasons for the poor utilization of surveillance even after publication of
the AASLD guidelines. Barriers to healthcare utilization are likely greater in the Medicaid
population. No studies have undertaken qualitative or quantitative research into patient
barriers to HCC surveillance, but factors such as poverty, lack of transportation or loss of
work hours have impacted screening for other diseases in Medicaid populations.(17) Others
may simply not see the importance of surveillance, reflecting poor health literacy. Dubard
and colleagues found that only approximately 50% of colorectal, breast and cervical cancer
screening exams recommended by primary care providers were actually obtained in a
similar NC Medicaid cohort.(14)
Provider attitudes play a crucial role as indicated by variation in surveillance rates for
patients seen by primary care physicians versus gastroenterologists. Our subjects were seen
twice as often by a primary care provider as compared to a gastroenterologist. However,
those seen by a gastroenterologist were nearly three times as likely to undergo imaging, an
effect that persisted among those patients only seen in the outpatient setting. The arguments
for HCC surveillance may be compelling to some, but not all health care professionals.(18)
Though endorsed by the AASLD and the European Association for the Study of the Liver
(EASL), the National Cancer Institute Physician Data Query (NCI P.D.Q.©) panel does not
support surveillance for HCC due to lack of evidence showing a clear mortality benefit.(19)
Alternatively, primary care providers may simply be unaware of surveillance guidelines.
Delayed uptake of specialty guidelines by primary care has been seen in other best-practice
scenarios.(20-24) Slow dissemination of best-practice guidelines may also explain why care
at academic centers increased the odds of surveillance in our study and others.(9) Providers
at academic centers have easier access to subspecialty conferences and continuing medical
education opportunities, particularly in the field of hepatology.
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Unlike other studies that suggest urban locale is associated with surveillance, our study
found no such association.(8) Ultrasound testing is available in most non-urban communities
in our state, so lack of an independent association is plausible. Data on the association
between alcohol abuse and surveillance are conflicting.(8) In our analysis, the effect of
alcohol abuse did not persist among those seen only in the outpatient setting suggesting that
the majority of exams ordered for alcoholic cirrhotics may have been for diagnostic
purposes in the acute care setting. The decreased imaging rate with age may be explained by
declining benefit of screening. This age effect did not persist in the outpatient setting
suggesting that the hospitalized elderly may be more ill and unable to withstand HCC
therapy thus obviating the need to screen.
Major strengths of our data include the large sample size and near-complete capture of billed
services including those also covered by Medicare. Only 8%-12% of NC Medicaid patients
are estimated to have supplemental non-Medicare insurance [personal communication
January 2011, Tara Larson, Chief Clinical Operations Office, N.C. Department of Health
and Human Services, (25)]. Even if all 12% covered by supplemental insurance underwent
imaging not captured in our dataset, the imaging rate would have risen to only 38%. We
used ICD-9 codes for cirrhosis that have previously been shown to have high positive (90%)
and negative (87%) predictive values for identifying patients with and without cirrhosis.(26)
These codes were validated in a VA population. We were unable to confirm validity in this
Medicaid cohort because the dataset contained only de-identified administrative data. To
address this, we performed subgroup analysis limited to patients with at least 2 and 3
repeated codes for cirrhosis, and the imaging rates were essentially the same. Additionally,
80% of patients with a cirrhosis code also had another liver diagnosis or a complication of
cirrhosis (e.g. hepatic encephalopathy, jaundice, ascites) suggesting misclassification bias
was probably minimal. We also limited our cohort to those without HCC, and even
exclusion of patients who developed HCC during the study period, did not change our
results significantly.
A significant weakness in our study is that only 30% of the cohort was seen in the outpatient
setting where health maintenance is typically addressed. Therefore our data probably reflects
poor access or utilization of outpatient care by Medicaid patients more than lack of HCC
surveillance by outpatient providers. Nevertheless, 30% of this large dataset still represents
1520 patients, and their imaging rate was less than 12%. In any case, the imaging rate is
abysmal, and our data highlight the challenges of providing preventive services to a cohort
that does not routinely present for outpatient care. As the incidence of HCC cases rises
overall, we will likely see mostly late-stage HCC in the Medicaid population due to the
decreased opportunities to screen. Better access and utilization of outpatient care are clearly
needed. For now, increased awareness of HCC surveillance guidelines by inpatient providers
may represent an opportunity to detect earlier-stage tumors in Medicaid patients who often
do not present for outpatient care without a compelling reason.
Another limitation of the data is the inability to differentiate between surveillance and
diagnostic exams, even in the outpatient setting. The database we used is robust in
diagnostic and procedural billing codes but lacks detailed clinical data such as clinical notes
or laboratory results. One study has used an algorithm to distinguish between surveillance
and diagnostic uses of AFP and ultrasound.(27) However, the algorithm used HIV status
which was not available in this dataset, and the algorithm was less helpful for ultrasound
compared to AFP. Practically speaking, any of the diagnostic imaging ascertained would be
considered sufficient for HCC surveillance even if it were ordered for other purposes. The
inability to identify the clinical intent of the imaging accomplished only biases our results
toward overestimating the true surveillance rate. Clearly, the rate of surveillance is
unacceptably low.
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Broad adoption of HCC surveillance may significantly reduce HCC mortality among
cirrhotics. However, current data suggests the guidelines are followed sparingly and have
had little penetration into non-gastroenterology practices for the Medicaid population. Few
Medicaid cirrhotics even present for outpatient care, and lack of uptake by the primary care
sector translates into very low surveillance rates overall. Much more must be done if the
guidelines are to have community effectiveness in the Medicaid population. Identification of
barriers to HCC surveillance among both patients and providers, recruitment of primary care
providers, and improved access to subspecialty care will be necessary. Such penetration into
the Medicaid population should not be dismissed as insurmountable. Ultrasound is available
in most rural and urban communities. The exam is relatively quick, painless and without the
discomfort that can be engendered by other screening exams such as pelvic exams,
colonoscopies and mammograms. Therefore, mitigation of barriers to surveillance through
establishment of educational and system interventions and improved utilization of outpatient
services could greatly improve outcomes for Medicaid patients with cirrhosis.
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Table 1












‡ - - -
Sex (female) 2,220 (44) 629 (27)
Race
    White 2,841 (56) 740 (26)
    African American 1,780 (35) 442 (25)
    Native American 91 (2) 21 (23)
    Asian American 27 (<1) 11 (41)
    Other/Unreported 322 (6) 81 (25)
Seen in an E.D.
§ 2,885 (57) 911 (31)
Hospitalized 2,379 (47) 876 (37)
Primary Care Visit(s) 2,429 (48) 730 (30)
Gastroenterology Visit(s) 1,063 (21) 503 (47)
Academic Center Care 1,113 (22) 504 (46)
Urban Residence 2,958 (58) 762 (26)
Medicare Dual-Eligibility 2,659 (53) 651 (50)
a
All data were derived from North Carolina Cost and Quality Initiative database for 2006-2007. The study population included all individuals over
the age of 18 with at least one recording of I.C.D.-9 code 571.2 (alcoholic cirrhosis of liver) or I.C.D.-9 code 571.5 (cirrhosis of liver without
mention of alcohol) and at least 15 months of continuous Medicaid enrollment during 2006-2007.
*
Percent of total sample (5,061)
†




E.D. = emergency department
























Alcohol related 2,991 (59) 821 (27)
Hepatitis C 1,493 (30) 615 (41)
Hepatitis B 205 (4) 100 (49)
Hemochromatosis 359 (7) 138 (38)
Alph-1 antitrypsin
  deficiency
5 (0.1) 1 (20)
Primary biliary cirrhosis 79 (2) 42 (53)
Cholangitis 32 (0.6) 27 (85)
Other chronic active
  hepatitis/ non-alcoholic
  liver disease
400 (8) 220 (57)
Unknown 1,207 (24) 170 (14)
*
Percent of total sample (5,061)
†
Percent of row total
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Table 3
Multivariable logistic regression model of factors associated with imaging
a








Sex (female) 1.18 (1.02, 1.37) 1.11 (0.95, 1.32)
Race
  White - - - -
  African American 0.93 (0.80,1.09) 1.11 (0.93,1.32)
  American Native 1.02 (0.59, 1.75) 1.02 (0.59, 1.75)





  Other/Unreported 1.00 (0.74,1.34) 1.00 (0.74,1.34)
Primary Care Visit 0.94 (0.76, 1.16) 1.02 (0.81, 1.29)
Gastroenterology Visit 2.81 (2.32, 3.41) 2.37 (1.91, 2.95)
Care in an Academic Center 2.13 (1.82, 2.50) 1.44 (1.21, 1.73)
Urban Residence 0.91 (0.78, 1.05) 0.96 (0.82, 1.14)
Medicare Dual-Eligibility 1.69 (1.38, 2.07) 1.74 (1.39, 2.18)
Cirrhosis Risk Factors
  Viral Hepatitis 1.98 (1.67, 2.35) 1.59 (1.32, 1.93)
  Alcohol Abuse 1.21 (1.00, 1.47) 1.33 (1.07, 1.66)
  Other 2.16 (1.79, 2.60) 2.07 (1.70, 2.53)
  Unknown 0.93 (0.71, 1.21) 0.97 (0.71, 1.32)
a
Adjusted for comorbidities and frequency of cirrhosis diagnostic codes
*
O.R. = Odds Ratio
†
C.I. = Confidence Interval
‡
Items are discrepant between the two models; Bolded items meet significance
J Clin Gastroenterol. Author manuscript; available in PMC 2014 September 01.
